| Company Name: |
BOC Sciences |
| Tel: |
+1-631-485-4226 |
| Email: |
inquiry@bocsci.com |
|
| | Surinabant Basic information |
| Product Name: | Surinabant | | Synonyms: | Surinabant;1-(2,4-Dichlorophenyl)-5-(4-bromophenyl)-4-ethyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide;5-(4-Bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-1-piperidinyl-1H-pyrazole-3-carboxamide;1H-Pyrazole-3-carboxamide, 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-1-piperidinyl-;SR 147778;SR147778;SR-147778;5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide | | CAS: | 288104-79-0 | | MF: | C23H23BrCl2N4O | | MW: | 522.26 | | EINECS: | | | Product Categories: | | | Mol File: | 288104-79-0.mol |  |
| | Surinabant Chemical Properties |
| density | 1.50 | | pka | 11.30±0.20(Predicted) |
| | Surinabant Usage And Synthesis |
| Uses | Surinabant (SR 147778) is an orally active, selective cannabinoid receptor type 1 CB1R antagonist. Surinabant is used in studies of obesity and alcoholism[1][2]. | | Definition | ChEBI: 5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-3-pyrazolecarboxamide is a member of pyrazoles and a ring assembly. | | References | [1] Klumpers LE, et al. Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans. Br J Clin Pharmacol. 2013 Jul;76(1):65-77. DOI:10.1111/bcp.12071 [2] Fischler PV, et al. Off-label and investigational drugs in the treatment of alcohol use disorder: A critical review. Front Pharmacol. 2022 Oct 3;13:927703. DOI:10.3389/fphar.2022.927703 |
| | Surinabant Preparation Products And Raw materials |
|